Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations

Medicine, Oncology, Pharmacotherapy +16

Cancer Statistics, 2001

Robert T. Greenlee, M. B. Hill-Harmon, Thomas S. Murray et al. · CA A Cancer Journal for Clinicians · 2001 · 3.3K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Endosonography-guided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment

M. J. Wiersema, Peter Vilmann, Marc Giovannini et al. · Gastroenterology · 1997 · 1.1K citations

Medicine, Oncology, Pathology +16

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

Eric Van Cutsem, Helgi van de Velde, Petr Karásek et al. · Journal of Clinical Oncology · 2004 · 774 citations · Full text

Medicine, Oncology, Pharmacology +12

Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate

Caio M. Rocha Lima, Mark R. Green, Robert Rotche et al. · Journal of Clinical Oncology · 2004 · 586 citations · Full text

Medicine, Oncology, Pharmacology +17